GSK plc (NYSE:GSK - Free Report) - Equities researchers at Zacks Research decreased their Q4 2024 EPS estimates for GSK in a research report issued to clients and investors on Tuesday, November 19th. Zacks Research analyst E. Bagri now expects that the pharmaceutical company will earn $0.63 per share for the quarter, down from their previous estimate of $0.76. The consensus estimate for GSK's current full-year earnings is $4.03 per share. Zacks Research also issued estimates for GSK's Q4 2025 earnings at $0.84 EPS, FY2025 earnings at $4.34 EPS, Q2 2026 earnings at $1.13 EPS and FY2026 earnings at $4.90 EPS.
Several other research firms have also issued reports on GSK. Jefferies Financial Group lowered GSK from a "buy" rating to a "hold" rating and dropped their target price for the stock from $53.00 to $39.50 in a report on Tuesday, November 12th. Deutsche Bank Aktiengesellschaft cut GSK from a "buy" rating to a "hold" rating in a research note on Friday, November 15th. Barclays upgraded shares of GSK to a "hold" rating in a research note on Tuesday, August 27th. Guggenheim downgraded GSK from a "buy" rating to a "neutral" rating in a research report on Thursday, October 31st. Finally, Argus raised GSK to a "strong-buy" rating in a report on Wednesday, August 7th. Seven investment analysts have rated the stock with a hold rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $43.25.
Read Our Latest Stock Report on GSK
GSK Trading Down 0.3 %
Shares of NYSE:GSK opened at $33.36 on Thursday. The company's 50-day moving average price is $38.46 and its two-hundred day moving average price is $40.49. GSK has a one year low of $32.83 and a one year high of $45.92. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.81 and a quick ratio of 0.53. The stock has a market capitalization of $69.14 billion, a PE ratio of 21.66, a price-to-earnings-growth ratio of 1.29 and a beta of 0.66.
Institutional Investors Weigh In On GSK
Several institutional investors have recently made changes to their positions in the stock. Eastern Bank acquired a new stake in shares of GSK during the 3rd quarter worth approximately $26,000. Sunbelt Securities Inc. lifted its stake in GSK by 73.8% during the third quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company's stock worth $29,000 after purchasing an additional 302 shares during the last quarter. Concord Wealth Partners boosted its stake in shares of GSK by 231.8% during the third quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company's stock valued at $32,000 after purchasing an additional 547 shares in the last quarter. Ashton Thomas Private Wealth LLC bought a new stake in shares of GSK during the second quarter worth about $37,000. Finally, Fortitude Family Office LLC acquired a new position in shares of GSK in the third quarter valued at approximately $42,000. 15.74% of the stock is currently owned by institutional investors.
Insider Transactions at GSK
In other GSK news, major shareholder Plc Gsk bought 2,791,930 shares of the firm's stock in a transaction on Friday, September 27th. The shares were purchased at an average price of $8.00 per share, for a total transaction of $22,335,440.00. Following the transaction, the insider now directly owns 16,775,691 shares in the company, valued at approximately $134,205,528. This trade represents a 19.97 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 10.00% of the company's stock.
GSK Increases Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, January 9th. Shareholders of record on Friday, November 15th will be given a dividend of $0.3928 per share. This is a boost from GSK's previous quarterly dividend of $0.38. The ex-dividend date is Friday, November 15th. This represents a $1.57 annualized dividend and a yield of 4.71%. GSK's dividend payout ratio (DPR) is presently 99.35%.
About GSK
(
Get Free Report)
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider GSK, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GSK wasn't on the list.
While GSK currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
